Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from Chardan Capital

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $24.00 price objective on the stock. Chardan Capital’s target price would indicate a potential upside of 174.60% from the stock’s current price.

STOK has been the topic of a number of other research reports. HC Wainwright increased their price target on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Stock Down 6.0 %

Stoke Therapeutics stock opened at $8.74 on Wednesday. The firm has a market cap of $462.93 million, a price-to-earnings ratio of -4.16 and a beta of 0.95. Stoke Therapeutics has a 52 week low of $5.20 and a 52 week high of $17.58. The business’s 50-day moving average price is $10.62 and its 200 day moving average price is $12.32.

Insiders Place Their Bets

In other news, CEO Edward M. Md Kaye sold 6,786 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $88,150.14. Following the completion of the sale, the chief executive officer now directly owns 61,885 shares of the company’s stock, valued at approximately $803,886.15. The trade was a 9.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares of the company’s stock, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock valued at $809,421 over the last quarter. 11.30% of the stock is owned by insiders.

Institutional Trading of Stoke Therapeutics

Institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS acquired a new position in Stoke Therapeutics in the 4th quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics in the 4th quarter valued at about $113,000. China Universal Asset Management Co. Ltd. acquired a new position in Stoke Therapeutics in the 4th quarter valued at about $124,000. Tower Research Capital LLC TRC increased its position in Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after purchasing an additional 4,918 shares during the period. Finally, Invesco Ltd. acquired a new position in Stoke Therapeutics during the 4th quarter worth approximately $133,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.